Old Drug Combo Prevents Colorectal Adenomas

SAN DIEGO — Small doses of two historic drugs administered in tandem profoundly reduced the development of colorectal adenomas in patients with prior adenoma formation, heralding a “mid-game home run” in secondary chemoprevention, investigators reported at the annual meeting of the American Association for Cancer Research.

Dr. Frank L. Meyskens Jr., professor of medicine and biological chemistry at the University of California, Irvine, presented late-breaking results from a phase III trial of difluoromethylornithine (DFMO), a synthetic inhibitor of ornithine decarboxylase, and sulindac (Clinoril), an NSAID, in 375 patients.

Patients were recruited following resection of at least one adenoma (3 mm or larger) discovered on colonoscopy—a history placing them at significant risk of recurrence.

Oral doses of DFMO (500 mg) and sulindac (150 mg) daily were given to 191 randomized patients, while 184 were assigned to placebo. Low-dose aspirin was used by approximately 40% of patients in each group.

At 3 years' follow-up, total adenomas detected by colonoscopy were reduced by 70%, advanced adenomas by 92%, and multiple adenomas by 95% in treated patients, compared with those on placebo.

Specifically, an adenoma was found in 42 of 97 patients who received placebo and completed the trial (43%), compared with 12 of 107 on the DFMO/sulindac combination (11%). Advanced adenomas—large, intramucosal or invasive adenomas with histologic features linked with conversion to colorectal cancer—were seen in nine (9.3%) patients in the placebo group and one patient receiving combination chemoprevention. More than one adenoma was found in 15 patients receiving placebo and 1 patient in the chemoprevention arm.

“These are absolutely stunning findings,” Dr. Scott M. Lippman told meeting attendees in a formal discussion of the phase III results. “I would consider this a mid-game home run.”

The research culminates a “long quest” by Dr. Meyskens and coinvestigator Dr. Eugene W. Gerner of the University of Arizona, Tucson, to fight the development of cancer by targeting ornithine decarboxylase, a key polyamine pathway that acts as an instigator of growth.

DFMO, long abandoned as chemotherapy because of inefficacy and hearing-related toxicity, was known to prevent many forms of cancer in preclinical and in vitro models. The researchers conducted novel “de-escalation” dose-finding trials, determining in the mid-1990s that a 500-mg dose (one-fiftieth of the therapeutic dose and one-quarter of the ototoxic dose) could reduce the polyamine content of colonic flat mucosa.

The decision was made to combine the drug (approved for African sleeping sickness and, more recently, as a topical depilatory) with sulindac, an NSAID in use for a half-century, to maximize each drug's efficacy at the smallest possible doses.

Sulindac has multiple mechanisms of action and was used in the trial at a 150-mg dose daily, half the dose used in the treatment of arthritis.

Adverse events were carefully monitored, with particular attention given to cardiovascular and otologic side effects previously associated with NSAIDs and DFMO.

At least one serious adverse event requiring hospitalization was seen in 31 patients receiving placebo and 42 patients in the DFMO/sulindac group. No significant difference was seen in the number of patients experiencing a serious adverse event.

Serious cardiovascular side effects occurred in 16 patients receiving active treatment versus 9 in the placebo arm. This difference, while not statistically significant, may indicate a “worrisome trend” and deserves more study, according to Dr. Lippman of the M.D. Anderson Cancer Center, Houston, a formal discussant of the study.

No hearing loss was perceived in patients receiving DFMO and sulindac, although a 1- to 2-dB difference was found in precise hearing tests. This difference is “a sound equivalent to rubbing your two fingers together,” Dr. Meyskens said. The hearing loss was reversible with discontinuation of the drug.

The DFMO/sulindac drug combination also has shown “very promising” results in early studies of prostate cancer and is being studied as a topical agent in skin cancers.

Future research may investigate its chemopreventive potential in patients with “cured” low-stage colorectal cancer, and a larger group of patients with prior advanced adenomas detected at colonoscopy.

However, because DFMO has gone off patent, creative solutions are being sought to finance future studies of the drug combination's potential as a chemopreventive agent, Dr. Meyskens said.

The study was published online simultaneously with the presentation at AACR (Cancer Prev. Res. 2008 April [Epub doi: 10.1158/1940-6207.CAPR-08-0042]).

SAN DIEGO — Small doses of two historic drugs administered in tandem profoundly reduced the development of colorectal adenomas in patients with prior adenoma formation, heralding a “mid-game home run” in secondary chemoprevention, investigators reported at the annual meeting of the American Association for Cancer Research.

Dr. Frank L. Meyskens Jr., professor of medicine and biological chemistry at the University of California, Irvine, presented late-breaking results from a phase III trial of difluoromethylornithine (DFMO), a synthetic inhibitor of ornithine decarboxylase, and sulindac (Clinoril), an NSAID, in 375 patients.

Patients were recruited following resection of at least one adenoma (3 mm or larger) discovered on colonoscopy—a history placing them at significant risk of recurrence.

Oral doses of DFMO (500 mg) and sulindac (150 mg) daily were given to 191 randomized patients, while 184 were assigned to placebo. Low-dose aspirin was used by approximately 40% of patients in each group.

At 3 years' follow-up, total adenomas detected by colonoscopy were reduced by 70%, advanced adenomas by 92%, and multiple adenomas by 95% in treated patients, compared with those on placebo.

Specifically, an adenoma was found in 42 of 97 patients who received placebo and completed the trial (43%), compared with 12 of 107 on the DFMO/sulindac combination (11%). Advanced adenomas—large, intramucosal or invasive adenomas with histologic features linked with conversion to colorectal cancer—were seen in nine (9.3%) patients in the placebo group and one patient receiving combination chemoprevention. More than one adenoma was found in 15 patients receiving placebo and 1 patient in the chemoprevention arm.

“These are absolutely stunning findings,” Dr. Scott M. Lippman told meeting attendees in a formal discussion of the phase III results. “I would consider this a mid-game home run.”

The research culminates a “long quest” by Dr. Meyskens and coinvestigator Dr. Eugene W. Gerner of the University of Arizona, Tucson, to fight the development of cancer by targeting ornithine decarboxylase, a key polyamine pathway that acts as an instigator of growth.

DFMO, long abandoned as chemotherapy because of inefficacy and hearing-related toxicity, was known to prevent many forms of cancer in preclinical and in vitro models. The researchers conducted novel “de-escalation” dose-finding trials, determining in the mid-1990s that a 500-mg dose (one-fiftieth of the therapeutic dose and one-quarter of the ototoxic dose) could reduce the polyamine content of colonic flat mucosa.

The decision was made to combine the drug (approved for African sleeping sickness and, more recently, as a topical depilatory) with sulindac, an NSAID in use for a half-century, to maximize each drug's efficacy at the smallest possible doses.

Sulindac has multiple mechanisms of action and was used in the trial at a 150-mg dose daily, half the dose used in the treatment of arthritis.

Adverse events were carefully monitored, with particular attention given to cardiovascular and otologic side effects previously associated with NSAIDs and DFMO.

At least one serious adverse event requiring hospitalization was seen in 31 patients receiving placebo and 42 patients in the DFMO/sulindac group. No significant difference was seen in the number of patients experiencing a serious adverse event.

Serious cardiovascular side effects occurred in 16 patients receiving active treatment versus 9 in the placebo arm. This difference, while not statistically significant, may indicate a “worrisome trend” and deserves more study, according to Dr. Lippman of the M.D. Anderson Cancer Center, Houston, a formal discussant of the study.

No hearing loss was perceived in patients receiving DFMO and sulindac, although a 1- to 2-dB difference was found in precise hearing tests. This difference is “a sound equivalent to rubbing your two fingers together,” Dr. Meyskens said. The hearing loss was reversible with discontinuation of the drug.

The DFMO/sulindac drug combination also has shown “very promising” results in early studies of prostate cancer and is being studied as a topical agent in skin cancers.

Future research may investigate its chemopreventive potential in patients with “cured” low-stage colorectal cancer, and a larger group of patients with prior advanced adenomas detected at colonoscopy.

However, because DFMO has gone off patent, creative solutions are being sought to finance future studies of the drug combination's potential as a chemopreventive agent, Dr. Meyskens said.

The study was published online simultaneously with the presentation at AACR (Cancer Prev. Res. 2008 April [Epub doi: 10.1158/1940-6207.CAPR-08-0042]).

SAN DIEGO — Small doses of two historic drugs administered in tandem profoundly reduced the development of colorectal adenomas in patients with prior adenoma formation, heralding a “mid-game home run” in secondary chemoprevention, investigators reported at the annual meeting of the American Association for Cancer Research.

Dr. Frank L. Meyskens Jr., professor of medicine and biological chemistry at the University of California, Irvine, presented late-breaking results from a phase III trial of difluoromethylornithine (DFMO), a synthetic inhibitor of ornithine decarboxylase, and sulindac (Clinoril), an NSAID, in 375 patients.

Patients were recruited following resection of at least one adenoma (3 mm or larger) discovered on colonoscopy—a history placing them at significant risk of recurrence.

Oral doses of DFMO (500 mg) and sulindac (150 mg) daily were given to 191 randomized patients, while 184 were assigned to placebo. Low-dose aspirin was used by approximately 40% of patients in each group.

At 3 years' follow-up, total adenomas detected by colonoscopy were reduced by 70%, advanced adenomas by 92%, and multiple adenomas by 95% in treated patients, compared with those on placebo.

Specifically, an adenoma was found in 42 of 97 patients who received placebo and completed the trial (43%), compared with 12 of 107 on the DFMO/sulindac combination (11%). Advanced adenomas—large, intramucosal or invasive adenomas with histologic features linked with conversion to colorectal cancer—were seen in nine (9.3%) patients in the placebo group and one patient receiving combination chemoprevention. More than one adenoma was found in 15 patients receiving placebo and 1 patient in the chemoprevention arm.

“These are absolutely stunning findings,” Dr. Scott M. Lippman told meeting attendees in a formal discussion of the phase III results. “I would consider this a mid-game home run.”

The research culminates a “long quest” by Dr. Meyskens and coinvestigator Dr. Eugene W. Gerner of the University of Arizona, Tucson, to fight the development of cancer by targeting ornithine decarboxylase, a key polyamine pathway that acts as an instigator of growth.

DFMO, long abandoned as chemotherapy because of inefficacy and hearing-related toxicity, was known to prevent many forms of cancer in preclinical and in vitro models. The researchers conducted novel “de-escalation” dose-finding trials, determining in the mid-1990s that a 500-mg dose (one-fiftieth of the therapeutic dose and one-quarter of the ototoxic dose) could reduce the polyamine content of colonic flat mucosa.

The decision was made to combine the drug (approved for African sleeping sickness and, more recently, as a topical depilatory) with sulindac, an NSAID in use for a half-century, to maximize each drug's efficacy at the smallest possible doses.

Sulindac has multiple mechanisms of action and was used in the trial at a 150-mg dose daily, half the dose used in the treatment of arthritis.

Adverse events were carefully monitored, with particular attention given to cardiovascular and otologic side effects previously associated with NSAIDs and DFMO.

At least one serious adverse event requiring hospitalization was seen in 31 patients receiving placebo and 42 patients in the DFMO/sulindac group. No significant difference was seen in the number of patients experiencing a serious adverse event.

Serious cardiovascular side effects occurred in 16 patients receiving active treatment versus 9 in the placebo arm. This difference, while not statistically significant, may indicate a “worrisome trend” and deserves more study, according to Dr. Lippman of the M.D. Anderson Cancer Center, Houston, a formal discussant of the study.

No hearing loss was perceived in patients receiving DFMO and sulindac, although a 1- to 2-dB difference was found in precise hearing tests. This difference is “a sound equivalent to rubbing your two fingers together,” Dr. Meyskens said. The hearing loss was reversible with discontinuation of the drug.

The DFMO/sulindac drug combination also has shown “very promising” results in early studies of prostate cancer and is being studied as a topical agent in skin cancers.

Future research may investigate its chemopreventive potential in patients with “cured” low-stage colorectal cancer, and a larger group of patients with prior advanced adenomas detected at colonoscopy.

However, because DFMO has gone off patent, creative solutions are being sought to finance future studies of the drug combination's potential as a chemopreventive agent, Dr. Meyskens said.

The study was published online simultaneously with the presentation at AACR (Cancer Prev. Res. 2008 April [Epub doi: 10.1158/1940-6207.CAPR-08-0042]).